Form 4 for SMMT Summit Therapeutics Inc.
Accepted 2022-12-08 00:00:00 ET · period of report 2022-12-06 · accession 0001387131-22-012236 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-08 | 2022-12-06 | SMMT | DUGGAN ROBERT W | CEO, Dir | J - Other | — | +9.35M | 171.88M | +6% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-06 | J | A | 9,346,434 | — | 171,879,226 | D | — | — | (F1) 9,346,434 shares of Common Stock were issued to the Reporting Person as payment of interest in connection with a Note Purchase Agreement, dated December 6, 2022, by and among the Issuer, the Reporting Person and Dr. Maky Zanganeh. The determination of the number of shares of Common Stock to be issued to the Reporting Person was based on a per share price of $0.79. |